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increase hepcidin production, there was no 
correlation between hepcidin and in% am-
mation markers such as C-reactive protein 
and interleukin-6 in predialysis patients, 
nor in hemodialysis patients. (4) Plasma 
levels of growth diE erentiation factor 15 
(GDF15), a member of the BMP /
 transforming growth factor-  superfamily, 
were positively correlated with plasma 
hepcidin levels in predialysis but not in 
dialysis patients. 
  ese results suggest that iron regulation 
in CKD patients might be more complex 
than we initially thought. In CKD patients, 
there are several abnormal factors, some of 
which may increase, whereas others 
decrease, hepcidin levels. In dialysis 
patients, additional factors may further 
modify iron metabolism through or inde-
pendently of hepcidin. We still have no idea 
how these factors aE ect hepcidin and iron 
metabolism in these patients.  erefore, 
contrary to our initial expectations, hepci-
din may not be the major player in abnor-
mal iron  metabolism in CKD. Nevertheless, 
further studies with easier assays for hepci-
din-25 would certainly provide answers to 
these questions in the future, once sensitiv-
ity and specificity of these assays are 
 con& rmed. 
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 Figure 1  |  Roles and regulation of hepcidin in chronic kidney disease. In chronic kidney disease 
(CKD) patients, including dialysis patients, there are various factors that may increase or decrease serum 
hepcidin levels. The total effects of these factors have not yet been fully clarified. Hepcidin may not be 
the star player in abnormal iron metabolism in CKD as we had originally expected. Epo, erythropoietin; 
GFR, glomerular filtration rate; Hb, hemoglobin. (  +  ), increase; (  −  ), decrease; ?, unproven. 
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 Fetuin – mineral complex: 
a new potential biomarker 
for vascular calcification? 
 Hirotaka  Komaba 1 and  Masafumi  Fukagawa 1 
 Vascular calcification is prevalent in dialysis patients and is associated with a 
high burden of cardiovascular disease. Fetuin-A is a potent inhibitor of 
vascular calcification, but the precise mechanism by which it mediates 
vascular calcification in uremia is unclear. Matsui and colleagues 
demonstrate that circulating fetuin-A forms fetuin – mineral complex in the 
serum of uremic rats and thereby inhibits vascular calcification. This 
suggests that fetuin – mineral complex may reflect extraosseous calcification 
stress, opening new perspectives on vascular calcification in uremia. 
 Kidney International (2009)  75, 874 – 876.  doi: 10.1038/ki.2009.52 
(CKD) receiving dialysis treatment and 
contributes to cardiovascular morbidity 
and mortality. Until recently, it has been 
believed that extraosseous calci& cation in 
uremic patients is a passive process of 
 calcium phosphorus precipitation caused 
by supersaturation; however, recent basic 
and clinical data support the notion that 
vascular calcification, like skeletal 
see original article on page 915
 Vascular calci& cation frequently occurs in 
patients with chronic kidney disease 
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 osteogenesis, is an active, cell-mediated 
process that is regulated by various calci-
& cation inducers and inhibitors. 1 
 Fetuin-A, a 62 – kDa hepatocyte-derived 
glycoprotein, represents a potent inhibitor 
of hydroxyapatite formation.  e decisive 
role of fetuin-A was con& rmed in fetuin-A 
knockout mice, which presented 
with extensive, fatal calci& cation of soB  
tissues when crossed onto a strain of 
calci& cation-prone mice or when fed a 
phosphorus- and vitamin D – enriched 
diet. 2 In patients with end-stage renal 
 disease, its circulating levels are signi& -
cantly reduced, and several studies showed 
that a lower serum fetuin-A concentration 
was associated with increased all-cause 
and cardiovascular mortality in dialysis 
patients. 3,4 
 Of importance, fetuin-A is a multifunc-
tional protein that can modulate vascular 
calci& cation via at least two distinct mech-
anisms ( Figure 1 ). First, fetuin-A can 
locally inhibit calci& cations in the walls of 
the blood vessels.  ere, it is internalized 
by vascular smooth muscle cells (VSMCs) 
and incorporated into the matrix vesicles 
from apoptotic and viable VSMCs, which 
results in inhibition of mineral nuclea-
tion. 5 It also inhibits VSMC apoptosis and 
enhances phagocytosis of vesicles, thus 
further limiting their ability to mineralize 
the vasculature. 5 Second, fetuin-A acts 
systemically by binding excess mineral 
and forming fetuin – mineral complex, also 
called calcitropin particles, thereby 
increasing their solubility in a manner 
reminiscent of the means by which 
 apolipoproteins solubilize lipids.  e dis-
covery of fetuin – mineral complex was 
& rst reported by Price  et al. in the serum 
of rats treated with the bisphosphonate 
etidronate; 6 the appearance of this 
 complex in serum correlated with the 
inhibition of bone mineralization by etid-
ronate.  Subsequent studies showed that 
fetuin – mineral complex is formed in 
the course of fetuin-mediated arrest of 
 crystallization. 7 
 Matsui  et al. 8 (this issue) investigated the 
nature of fetuin – mineral complex in the 
pathogenesis of vascular calcification, 
using a rat model of adenine-induced renal 
failure.  ey con& rmed the presence of 
fetuin – mineral complex using matrix-
assisted laser desorption / ionization – time 
of % ight (MALDI – TOF) mass spectrom-
etry of the pellets formed by centrifugation 
of the serum of rats with adenine-induced 
renal failure that had ongoing arterial 
calcification. The inhibition of bone 
resorption with alendronate completely 
prevented the appearance of fetuin – min-
eral complex concomitantly with the 
elimination of vascular calci& cation. An 
additional  in vitro study revealed that the 
formation of these complexes contributed 
to the inhibition of spontaneous mineral 
precipitation. 
 Although it was previously reported 
that fetuin-A can inhibit ectopic calci& ca-
tion by forming fetuin – mineral complex, 
its role in uremia is an important addition 
to the literature, given that renal failure is 
a critical factor contributing to vascular 
calci& cation. Formation of fetuin – mineral 
complex in blood may also contribute to 
the prevention of vascular calci& cation in 
patients with CKD. Of importance, the 
formation of fetuin – mineral complex 
preceded the appearance of vascular 
calci& cation, suggesting that the appear-
ance of these complexes in the circulation 
may predict future development of 
vascular calci& cation. 
 Although several clinical studies have 
shown that low serum fetuin-A concentra-
tions are associated with poor outcome in 
dialysis patients, 3,4 other studies showed 
no correlation or even an inverse correla-
tion between outcome and serum levels. 9 
 ere are several possible explanations 
for these conflicting data. Given that 
fetuin-A is a multifunctional molecule (for 
example, transforming growth factor-  
antagonism, modification of insulin 
 receptor – mediated growth eE ects), its role 
in cardiovascular disease may be 
 modulated by various independent 
 patho genic  factors, such as in% ammation, 
insulin resistance, and uremic milieu. 
Besides, the formation of fetuin – mineral 
complex and its clearance from serum may 
cause the reduction of total levels of fetuin-
A, which may partly contribute to the dis-
crepancies between these studies. 
 It is tempting to expect that measure-
ments of serum fetuin – mineral complex 
levels may be useful for the assessment of 
extraosseous calci& cation stress in CKD 
patients. However, there are no clinical 
data at present that con& rm the presence 
of these complexes in human serum. 
Recently, larger mineral complexes con-
taining fetuin-A and other serum 
 proteins, referred to as secondary calc-
itropin particles, were isolated from the 
ascitic % uid of a peritoneal dialysis patient 
with calcifying peritonitis. 10 Whether the 
formation of fetuin – mineral complex, or 
 Figure 1 l Possible mechanisms for inhibition of vascular calcification by fetuin-A. Fetuin-A 
inhibits vascular calcification in both a local and a systemic manner. At sites of vascular damage, 
fetuin-A is incorporated into intracellular vesicles in vascular smooth muscle cells (VSMCs), and 
then released within apoptotic bodies and matrix vesicles, where it potently limits their ability to 
nucleate basic calcium phosphate. Fetuin-A also buffers mineral ion supersaturation by forming 
fetuin–mineral complex, also referred to as calcitropin particles, which represents another 
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 Tissue proteomics:
a new investigative tool
for renal biopsy analysis 
 John R.  Sedor 1 , 2 , 3 
 Renal biopsy is viewed as the gold standard for diagnosis and 
management of many kidney diseases, especially glomerulopathies. 
However, the histopathological descriptions currently used in clinical 
practice often are neither diagnostic nor prognostic. The paper 
by Sethi  et al. highlights the availability of a newer investigative 
tool that can be used to better define pathogenesis and, perhaps 
more important, to discover  robust biomarkers of kidney disease 
cause and outcome. 
 Kidney International (2009)  75, 876 – 879.  doi: 10.1038/ki.2009.54 
see original article on page 952
 Renal biopsy: more than a picture 
 Renal biopsy has long been used to di-
agnose and manage both acute and 
chronic kidney diseases, especially re-
nal dysfunction caused by glomerular 
injury. Despite elegant descriptions by 
talented investigative and clinical renal 
pathologists, the impact of renal biopsy 
on patient outcomes remains subopti-
mal. From a clinical perspective, his-
topathology  oB en is neither diagnostic 
nor prognostic and fails to predict re-
sponse to therapy of individuals within a 
given glomerular histopathological cat-
egory. Less-than-de& nitive data gleaned 
from kidney  biopsies may re% ect the 
heterogeneity of pathogenetic molecu-
lar mechanisms, that generate clinically 
indistinguishable histology. We have 
learned from molecular genetics that 
although diE erent  genetic variants can 
cause identical kidney pathologies, the 
treatments should be diE erent. For ex-
ample, patients with focal segmental 
glomerulosclerosis on biopsy can be 
steroid-responsive if the  mutation is in 
the gene encoding phospholipase C-ε 
but steroid-resistant if the mutation is 
in the gene encoding podocin or the ion 
 channel TRPC6. In addition to genetic 
mechanisms, molecular characteriza-
tion of kidney biopsies using  in situ 
hybridization and immunohistochem-
istry to characterize the diE erentiation 
state of endogenous kidney cells,  in% ux 
of leukocytes, and local networks of 
more advanced forms of the complex, can 
occur in the circulation of CKD patients 
needs to be con& rmed in future studies. 
In addition, the pathway by which the 
formed fetuin – mineral complex is cleared 
from serum also awaits elucidation. 
Finally, we would like to mention a 
 practical problem: the method for identi-
fying these complexes is currently too 
demanding for the majority of investiga-
tors. Development of a new assay that 
specifically measures fetuin – mineral 
complex would further expand this & eld 
of research. 
 In conclusion, Matsui  et al. 8 report a 
promising eE ect of fetuin-A to prevent 
vascular calci& cation by forming fetuin –
 mineral complex in an experimental model 
of uremia.  e formation of these com-
plexes may re% ect a response against extra-
osseous calci& cation stress and may lead to 
novel approaches to identifying individu-
als at high risk for vascular calci& cation. 
Future studies should examine whether 
measurement of fetuin – mineral complex 
can be used as a potential biomarker to 
guide strategies for the treatment of min-
eral and bone disorder in CKD patients. 
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